Health Condition 1: H401- Open-angle glaucoma
Conditions
Interventions
Intervention1: Netarsudil plus Timolol: Netarsudil 0.02 percent administered topically to eye once daily in night for three month and Timolol 0.5 percent used in eye topically twice daily for three mo
Sponsors
Northern Railway Central Hospital Basant Lane Aram Bag Paharganj New Delhi
Eligibility
Inclusion criteria
Inclusion criteria: 1. Already diagnosed case of POAG on one of the standard drug that will be Timolol 0.5 percent eye drop for more than 1month. 2. Age at least 45 years and above. 3 .IOP more than 17mmhg and less than 25 mmhg. 4. BCVA 6/9 or better by Snellens chart.
Exclusion criteria
Exclusion criteria: Any ocular disease likely to affect IOP. Any pathology of eye affecting media clarity. Any infective /inflammatory pathology of eye at screening time. Any ocular trauma in last 6 month . CCT OF patients more than 625 micron. Hypertension. Advanced changes of glaucomatous optic nerve.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To compare the IOP reduction between the combination therapy of netarsudil with timolol versus timolol monotherapy calculated by averaging the mean IOP over a period of 3 month. Timepoint: 3 month | — |
Secondary
| Measure | Time frame |
|---|---|
| The ocular safety variables with netarsudil are ocular symptoms like dry eyes, ,corneal deposits, corneal verticillata ,conjunctival hemorrhage ,corneal staining ,headaches, blurry vision,instillation site pain, erythema.Timepoint: 3 month | — |
Countries
India
Contacts
Public ContactShailender Kumar Choudhary
Norhtern Railway Central Hospital
Outcome results
None listed